Mark Massaro

BTIG | Healthcare

Mark Massaro is an analyst from BTIG specializing in the Healthcare sector. Ranked #1681 out of 4641 analysts, they have issued 59 stock ratings with a success rate of 92.27% and an average return of 7.56%.

Mark Massaro has a well-established track record, with 59 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 92.27% and an average return of 7.56%, underscoring their expertise and ability to identify winning opportunities for investors.

#1681

Out of 4641

59

Total Ratings

+92.27%

Success Rate

+7.56%

Average Return

Recent Ratings Analysis

SOPH

May 06, 2026

Target

$8.00

Current

$5.02

Performance

0.00%

Mark Massaro rated SOPH as Buy on May 06, 2026, setting a price target of 8. Shares have remained stable near 5.02, leaving the 8 target still in play.

ADPT

May 06, 2026

Target

$22.00

Current

$14.43

Performance

0.00%

On May 06, 2026, ADPT was given a Buy rating by Mark Massaro, with a target price of 22. The stock traded sideways with a 0.00% move, keeping the bullish thesis unresolved.

WGS

May 05, 2026

Target

$90.00

Current

$34.71

Performance

0.58%

WGS received a Buy rating from Mark Massaro on May 05, 2026, aiming for 90. Price action was muted, as shares hovered around 34.71 despite the bullish outlook.

CERS

May 01, 2026

Target

$4.00

Current

$2.59

Performance

—

On May 01, 2026, Mark Massaro published a Buy outlook on CERS, with a target of 4. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 2.59.

CDNA

Apr 29, 2026

Target

$28.00

Current

$20.95

Performance

0.72%

Mark Massaro on Apr 29, 2026 assigned CDNA a Buy rating, with a price target of 28. The recommendation remains pending validation as shares consolidate around 20.95.

LUCD

Mar 30, 2026

Target

$2.50

Current

$1.08

Performance

-6.09%

On Mar 30, 2026, Mark Massaro reaffirmed LUCD with a Buy rating, targeting 2.5. Shares slid 6.09% despite the recommendation, highlighting downside risks.

DNA

Mar 12, 2026

Target

$9.00

Current

$10.08

Performance

57.50%

DNA was rated Sell by Mark Massaro on Mar 12, 2026, with a price objective of 9. Bearish sentiment was justified as the stock retreated to 10.08.

XGN

Mar 10, 2026

Target

$10.00

Current

$3.09

Performance

-4.92%

On Mar 10, 2026, Mark Massaro initiated coverage on XGN with a Buy rating and target of 10. Neutral price movement of -4.92% leaves room for interpretation.

BLLN

Mar 05, 2026

Target

$160.00

Current

$81.40

Performance

—

Mark Massaro issued a Buy recommendation for BLLN on Mar 05, 2026, price target set at 160. The target of 160 remains in play, though confirmation will depend on future moves.

CAI

Feb 27, 2026

Target

$45.00

Current

$19.13

Performance

-5.01%

On Feb 27, 2026, CAI was evaluated by Mark Massaro, who gave a Buy rating and target of 45. Investors saw limited payoff as shares fell short of the 45 target.

TEM

Feb 25, 2026

Target

$105.00

Current

$53.50

Performance

-0.39%

Mark Massaro rated TEM as Buy on Feb 25, 2026, setting a price target of 105. Shares have remained stable near 53.5, leaving the 105 target still in play.

GH

Feb 20, 2026

Target

$145.00

Current

$92.25

Performance

-10.52%

On Feb 20, 2026, GH was given a Buy rating by Mark Massaro, with a target price of 145. Despite the Buy call, shares fell from 92.25 to 92.25, challenging the optimistic stance.

PSNL

Feb 11, 2026

Target

$13.00

Current

$6.07

Performance

-31.80%

PSNL received a Buy rating from Mark Massaro on Feb 11, 2026, aiming for 13. The rating hasn’t played out as hoped, with the stock trading 31.80% below expectations.

IDXX

Feb 03, 2026

Target

$800.00

Current

$579.23

Performance

-8.43%

On Feb 03, 2026, Mark Massaro published a Buy outlook on IDXX, with a target of 800. Market action contradicted the Buy thesis, as shares slipped to 579.23.

MDXH

Dec 23, 2025

Target

$7.00

Current

$2.02

Performance

-41.79%

Mark Massaro on Dec 23, 2025 assigned MDXH a Buy rating, with a price target of 7. The call has struggled to gain traction, with shares losing 41.79%.

CSTL

Dec 12, 2025

Target

$50.00

Current

$24.75

Performance

-35.93%

On Dec 12, 2025, Mark Massaro reaffirmed CSTL with a Buy rating, targeting 50. Shares slid 35.93% despite the recommendation, highlighting downside risks.

NTRA

Dec 05, 2025

Target

$260.00

Current

$215.09

Performance

-12.05%

NTRA was rated Buy by Mark Massaro on Dec 05, 2025, with a price objective of 260. This case shows how bullish projections can fail, with the stock now below 215.09.

ZTS

Dec 03, 2025

Target

$160.00

Current

$111.22

Performance

-9.26%

On Dec 03, 2025, Mark Massaro initiated coverage on ZTS with a Buy rating and target of 160. The Buy call has yet to be validated as shares remain 48.78 away from the target.

EXAS

Nov 20, 2025

Target

—

Current

$104.91

Performance

4.21%

Mark Massaro issued a Neutral recommendation for EXAS on Nov 20, 2025, price target set at null. The rating was appropriate for a consolidating market trading near 104.91.

MXCT

Aug 11, 2025

Target

—

Current

$0.85

Performance

-35.86%

On Aug 11, 2025, MXCT was evaluated by Mark Massaro, who gave a Neutral rating and target of null. The Hold call avoided chasing into subsequent weakness of 35.86%.

AKYA

May 14, 2024

Target

$6.00

Current

$1.29

Performance

-55.52%

Mark Massaro rated AKYA as Buy on May 14, 2024, setting a price target of 6. The stock has underperformed, dropping 55.52% despite the bullish target of 6.

NEO

May 02, 2024

Target

$21.00

Current

$8.89

Performance

-39.61%

On May 02, 2024, NEO was given a Buy rating by Mark Massaro, with a target price of 21. Despite the Buy call, shares fell from 8.89 to 8.89, challenging the optimistic stance.

Frequency Asked Questions

Who is Mark Massaro?

Mark Massaro is an analyst from BTIG specializing in the Healthcare sector.

What is Mark Massaro's success rate?

Mark Massaro currently has a success rate of +92.27%.

How many ratings has Mark Massaro issued?

Mark Massaro has issued 59 stock ratings so far.

What is the average return of Mark Massaro's calls?

Their stock ratings have generated an average return of +7.56%.

What is Mark Massaro's ranking?

Mark Massaro is ranked #1681 out of 4641 analysts.

What types of ratings does Mark Massaro give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Mark Massaro?

You can follow Mark Massaro by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Mark Massaro?

Their latest rating was a Buy on SOPH issued on 2026-05-06.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep